Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Potassium calcium-activated channel subfamily N member 4 (KCa3.1), encoded by the KCNN4 gene on chromosome 19q13.2, is an intermediate-conductance, voltage-independent potassium channel activated by intracellular calcium via calmodulin binding, forming homotetramers with six transmembrane domains and a selective K+ pore. It drives K+ efflux, causing membrane hyperpolarization that sustains Ca2+ influx essential for processes like T-lymphocyte activation, vascular smooth muscle proliferation, erythrocyte volume control (Gardos channel), and epithelial secretion. Expressed in T cells, macrophages, smooth muscle, endothelium, erythrocytes, and secretory epithelia, KCa3.1 regulates immune responses, vascular tone, and fluid transport. Dysregulation contributes to thrombotic diseases via smooth muscle hyperplasia and inflammation, cancers through enhanced tumor migration and survival, sickle cell dehydration, renal fibrosis, and hypertension. Pharmacological blockers like TRAM-34 and clotrimazole inhibit these pathological effects by disrupting Ca2+ signaling without broad toxicity, positioning KCa3.1 as a tractable therapeutic target in oncology, vascular, and inflammatory disorders.
Blockade inhibits K+ efflux, reducing Ca2+ influx, cell proliferation, migration, and activation in smooth muscle, T cells, macrophages Selective pore block prevents hyperpolarization-dependent Ca2+ signaling
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Potassium calcium-activated channel subfamily N member 4 (KCa3.1) (KCa3.1).